The Indianapolis-based drugmaker finally won FDA approval for its antidepressant Cymbalta to treat chronic pain and fended off a patent challenge to rising-star cancer drug Alimta, but got a ratings downgrade on its debt.
A U.S. District Court judge on Monday upheld Eli Lilly and Co.’s patent on the cancer drug Alimta, protecting the compound until July 2016. It was a welcome win after a difficult few months for Indianapolis-based Lilly, which is facing a wave of patent expirations in coming years.
Lilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications for autoimmune diseases.
A federal audit recommends that Indiana's human services agency refund the federal government nearly $39 million it overpaid to Medicaid providers during a nine-year period.
Merck & Co. is betting it can succeed where Pfizer Inc. failed, with a new type of drug to combat heart disease by raising good cholesterol levels. Indianapolis-based Eli Lilly and Co. is testing a similar pill.
Could nurse practitioners get a promotion in the medical field? At least one health insurer is treating them like doctors now.
Eli Lilly and Co.’s $800 million acquisition of Avid Radiopharmaceuticals Inc. is the biggest step yet in the drugmaker’s attempt to add diagnostics to its product portfolio.
A study at the Center for Health Policy at IUPUI found that 66 cents of every dollar the state spends on services related to substance abuse goes toward health care while only 1 cent goes toward prevention or intervention.
The Food and Drug Administration has cleared Cymbalta for musculoskeletal pain such as arthritis and chronic lower back conditions, which could mean another $500 million in annual sales for Lilly, an analyst estimates.
Businessman J.B. Carlson is in debt for $5.9 million, and he may have been the last person to see 74-year-old Suzy Tomlinson alive. Her $15 million life-insurance policy named him as the beneficiary.
In Utah, employers can give each of their workers a specific amount of money to apply toward health insurance. The worker then can use that money to choose from the 66 plans in the health insurance exchange.
The federal legislation is roundly criticized at a BioCrossroads meeting, but some firms have found a silver lining.
The Indianapolis-based health insurer raised its full-year profit forecast by 20 cents per share, after lower-than-expected claims and lower administrative costs increased third-quarter profit by 1 percent.
Jim Hamilton, an employee-benefits lawyer at Bose McKinney & Evans in Indianapolis, discussed the likelihood of a Republican-controlled U.S. House of Representatives changing or even outright repealing the health care reform law, formally known as the Patient Protection and Affordable Care Act.
Excluding investment and special charges, the Carmel-based life and health insurer on Tuesday reported a profit $47.1 million, down 13 percent from the same quarter a year ago, but still beat analysts’ expectations.
After recently deciding to close a research center in Singapore, Indianapolis-based Eli Lilly and Co. has decided to open a diabetes research center in China in the second half of 2011, further ramping up the drugmaker’s presence in the world’s fastest-growing pharmaceutical market.
Indianapolis-based Eli Lilly and Co. plans to open a diabetes research center in China, the drugmaker said Tuesday, citing the high incidence of the disease there.
Indiana’s life sciences industry has weathered the recession relatively well, but Eli Lilly’s struggles and tight capital markets could threaten the future.
St. Louis-based Ascension Health announced Friday morning that it would open a professional service center in Indianapolis, creating up to 500 jobs by 2013.
Carmel-based insurance lender Oak Street Funding LLC announced Thursday that it has been purchased by private equity funds managed by New York-based Angelo Gordon & Co.
